With $6.5M, Kanurra wants PBMs to show their work

Pharmacy benefit managers sit between employers, pharmacies, drugmakers, and patients, and the economics can hide who earned what. Kanurra is building a PBM designed to expose that chain, and the New York company has announced $6.5M in financing to push the model into live employer health plans.

Kanurra targets self-funded and level-funded employers, especially small and midsize groups that often get pharmacy benefits inside a larger insurance or administration package. It says it charges one fixed per-employee-per-month fee, passes drug costs through without spread pricing, and credits 100% of rebates back to the plan. Its website shows claim-level ledgers that break out acquisition cost, dispensing fee, rebate, Kanurra markup, and final plan cost.

The September 29 company release names Necessary Ventures, Asylum Ventures, Daybreak Ventures, Virtue VC, Ford Street Ventures, and Browder Capital as investors. No lead investor or valuation was disclosed, and the release does not state a formal round stage; secondary deal sources classify the financing as Seed. The amount also deserves precise accounting: the release says $6.5M, while an earlier founder disclosure and several deal databases reported $6.35M from the same core investor group. Public evidence does not establish whether the difference is rounding or an incremental close.

Kanurra says the capital will help expand the number of covered lives and build infrastructure for partners and enrollees, with hiring across clinical pharmacy, implementation and operations, broker and TPA-focused sales, and engineering.

The business model is a direct response to the economics of the incumbents. A January 2025 Federal Trade Commission staff report found that the Big 3 PBMs' affiliated pharmacies marked up many analyzed specialty generic drugs by hundreds or thousands of percent, estimating more than $7.3B in dispensing revenue above estimated acquisition cost from 2017 through 2022 plus an estimated $1.4B in spread-pricing income on the analyzed specialty generics. Kanurra is positioning its flat fee against that structure: the plan pays the pharmacy cost, sees rebates credited to the claim as they arrive, and pays Kanurra a separate fixed administrative fee that does not rise with drug spend.

The product promise goes beyond a lower invoice. Kanurra says employers can inspect claims, rebates, formulary decisions, and the criteria behind prior authorization. It also says its AI can approve clean prior-authorization cases while routing anything outside the pathway to a licensed clinician, with AI barred from issuing denials. Those are company-reported operating claims, not independently audited performance results. The savings examples on its site are labeled representative, with actual claims expected to differ.